Achillion Pharma (ACHN) Raises $50M from Recent Share Sale
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall St set to open higher as oil slips; telecoms hit by SpaceX spectrum deal
- Oil falls as Trump comments on Iran talks ease supply concerns
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts ACHN Hot Sheet
Price: $0.79 --0%
Financial Fact:
Total operating expenses: 21.55M
Today's EPS Names:
HOVR, VFS, PGR, More
Financial Fact:
Total operating expenses: 21.55M
Today's EPS Names:
HOVR, VFS, PGR, More
Join SI Premium – FREE
Between December 22, 2014 and December 31, 2014, Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) (the “Company”) sold shares of its common stock pursuant to the Sales Agreement, dated November 8, 2012, between the Company and Cantor Fitzgerald & Co., resulting in aggregate gross proceeds to the Company of $50 million. After giving effect to these sales, the Company estimates that its cash will be sufficient to meet its projected operating requirements into the fourth quarter of 2016.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- SuperCom wins two Texas electronic monitoring contracts
- Victoria's Secret CLO Melinda McAfee to leave company by March 2027
Create E-mail Alert Related Categories
Corporate News, Equity Offerings, GuidanceRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
